ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 173. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trialof long-term moderate exercise training in chronic heart failure: effectson functional capacity, quality of life, and clinical outcome. Circulation.1999;99(9):1173-82. 174. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercisetrainingmeta-analysisoftrials inpatientswithchronicheart failure. BMJ. 2004;328(7433):189. 175. O’Connor CM, Whellan DJ, LeeKL, Keteyian SJ, Cooper LS, Ellis SJ, et al. Efficacyand safetyofexercisetraining inpatientswithchronicheart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-50. 176. Cooper LB, Mentz RJ, Sun JL, Schulte PJ, Fleg JL, Cooper LS, et al. Psychosocial factors, exercise adherence, and outcomes in heart failure patients: insightsfromheartfailure:acontrolledtrial investigatingoutcomes of exercise training (HF-ACTION). Circ Heart Fail. 2015;8(6):1044-51. 177. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, et al. Exercise- based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014 Apr 27;(4):CD00333. 178. OliveiraMF,SantosRC,ArtzSA,MendezVMF,LoboDML,CorreiaEB,etal. Safety and efficacy of aerobic exercise training associated to non-invasive ventilation in patients with acute heart failure.Arq Bras Cardiol. 2018; 110(5):467-75. 179. Tucker WJ, Nelson MD, Beaudry RI, Halle M, Sarma S, Kitzman DW, et al. Impact of exercise training on peak oxygen uptake and its determinants in heartfailurewithpreservedejectionfraction.CardFailRev.2016;2(2):95-101. 180. Nolte K, Herrmann-Lingen C, Wachter R, Gelbrich G, Dungen H-D, Duvinage A, et al. Effects of exercise training on different quality of life dimensions in heart failurewith preserved ejection fraction: the Ex-DHF-P trial. Eur J Prev Cardiol. 2015;22(2):582-93. 181. Edelmann F, GelbrichG, DüngenH-D, Frohling S,Wachter R, Stahrenberg R, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2011;58(17):1780-91. 182. Pearson MJ, Mungovan SF, Smart NA. Effect of exercise on diastolic functionl in heart failure patients: a systematic reviewand meta-analysis. Heart Fail Rev. 2017;22(2):229-42. 183. Ferraz AS, Bocchi EA, Guimarães GV, Meneghelo RS, Umeda II, Sousa JE. Low intensity is better than high intensity exercise training in chronic heart failure patients concerning pulmonary ventilation, brain natriuretic peptide, and quality of life evaluation: A prospective randomized study. J Am Coll Cardiol. 2003;41(Suppl A):182A. 184. EllingsenØ,HalleM,ConraadsV,StøylenA,DalenH,DelagardelleC,etal. High-intensity interval trainingin patients with heart failure with reduced ejection fraction. Circulation. 2017;135(9):839-49. 185. Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal HM, Lough F, et al. Exercise- based rehabilitation for heart failure: systematic review andmeta-analysis Open Heart. 2015;2(2):e000163. 186. Winkelmann ER, Chiappa GR, Lima CO, Viecili PR, Stein R, Ribeiro JP. Addition of inspiratory muscle training to aerobic training imp roves cardiorespiratoryresponses to exercise in patients with heart failure and inspiratory muscleweakness. AmHeart J. 2009;158(5):768.e1-7. 187. Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, et al. Relationship between sick leave, unemployment, disability, and health- related quality of life in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2006;12(5):402-12. 188. Rørth R, Wong C, Kragholm K, Fosbøl EL, Mogensen UM, Lamberts M, et al.Return to the Workforce After First Hospitalization for Heart Failure Clinical Perspective. Circulation 2016;134(14):999–100. 189. Jaarsma T. Sexual function of patients with heart failure: facts and numbers. ESC Heart Fail. 2017;4(1):3–7. 190. Baumhakel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Böhm M. Cardiovascular risk, drugs and erectile function—a systematic analysis. Int J ClinPract. 2011;65(3):289-98. 191. Levine GN, Steinke EE, Bakaeen FG, Bozkurt B, Cheitlin MD, Conti JB, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125(8):1058-72. 192. Bocchi EA, Guimarães G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo- controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation. 2002; 106(9):1097-103. 193. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail. 2008;14(3):189-97. 194. Sedlak T, Merz NB, Shufelt C, Gregory KD, Hamilton MA. Contraception in patients with heart failure. Circulation 2012;126(11):1396–1400. 195. CohnJN,JohnsonG,ZiescheS,CobbF,FrancisG,TristaniF,etal.Acomparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. NEngl J Med. 1991;325(5):303-10. 196. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429-35. 197. Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN; SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractionsandcongestiveheart failure.NEngl JMed.1991;325(5):293-302. 198. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet. 1997;349(9064):1493-7. 199. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan comparedwith captopril onmortality in patients with symptomatic heart failure: randomized trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-7. 200. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, et al. Valsartan, captopril, orboth in myocardial infarction complicated by heart failure, left ventriculardysfunction, or both. N Engl J Med. 2003;349(20):1893-906. 201. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan inpatients with chronic heart failure and reduced left-ventricularsystolicfunctionintoleranttoangiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772-6. 202. LakhdarR,Al-MallahMH,LanfearDE.Safetyandtolerabilityofangiotensin- converting enzyme inhibitor versus the combination ofangiotensin- converting enzyme inhibitor and angiotensin receptorblocker in patients with left ventricular dysfunction: a systematic reviewandmeta-analysis of randomized controlled trials. J Card Fail. 2008;14(3):181-8. 203. McMurrayJJ,OstergrenJ,SwedbergK,GrangerCB,HeldP,MichelsonEL,et al. Effects of candesartan inpatients with chronic heart failure and reduced left-ventricular systolicfunction taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362(9386):767-71. 204. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. 205. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-7. 206. Packer M, Coats AJ, Fowler MB, Katus HA, KrumH, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8. 207. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al; COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7-13. 522